Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
New NCCN Imaging AUC released for eight new cancers

New NCCN Imaging AUC released for eight new cancers

The National Comprehensive Cancer Network, a Centers for Medicare & Medicaid Services-approved provider-led entity for imaging appropriate use criteria, continues to build its library of AUC and has published NCCN Imaging Appropriate Use Criteria for eight new cancer types. Launched in June 2016, NCCN Imaging AUC currently are available for 20 cancer types. [More]
The evolution of medical imaging – where will innovation take us next?

The evolution of medical imaging – where will innovation take us next?

The influence of medical imaging is constantly growing, diseases are detected earlier and treatments are becoming more effective. Within the last 25 years, cancer mortality rates have decreased by an impressive 25%. Advances in medical imaging have a big part to play in this achievement and we can expect that as technology continues to develop, mortality rates will drop even further. [More]
New genetic markers linked to fast rate of nicotine metabolism in smokers may raise risk for lung cancer

New genetic markers linked to fast rate of nicotine metabolism in smokers may raise risk for lung cancer

University of Hawai'i Cancer Center researchers discovered new genetic markers associated with a fast rate of nicotine metabolism, which potentially leads smokers to smoke more, thereby, increasing their risk for lung cancer. [More]
Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors. [More]
Study shows lymph node stage may have clinical importance among NSCLC patients with M1a disease

Study shows lymph node stage may have clinical importance among NSCLC patients with M1a disease

Analysis of a large non-small cell lung cancer (NSCLC) patient cohort with stage IV M1a disease identified lymph node staging as having clinical significance and an impact on prognosis. [More]
Researchers identify tantalizing target in fight against aggressive form of lung cancer

Researchers identify tantalizing target in fight against aggressive form of lung cancer

Researchers at the University of Virginia School of Medicine have discovered a flaw in the armor of the most aggressive form of lung cancer, a weakness that doctors may be able to exploit to slow or even stop the disease. [More]
Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. [More]
Added benefit of lung cancer drug not proven, says IQWiG

Added benefit of lung cancer drug not proven, says IQWiG

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have already received chemotherapy. [More]
Study highlights racial/ethnic disparities in genomic sequencing

Study highlights racial/ethnic disparities in genomic sequencing

As scientists learn more about which genetic mutations are driving different types of cancer, they're targeting treatments to small numbers of patients with the potential for big payoffs in improved outcomes. [More]
Moffitt research underscores importance of continued lung cancer screening in high-risk patients

Moffitt research underscores importance of continued lung cancer screening in high-risk patients

Lung cancer is the leading cause of cancer death for men and women. It is also one of the most complex cancers, both at the molecular level and through its clinical behavior. [More]
Computers could be more accurate than pathologists in assessing lung cancer tissues, study shows

Computers could be more accurate than pathologists in assessing lung cancer tissues, study shows

Computers can be trained to be more accurate than pathologists in assessing slides of lung cancer tissues, according to a new study by researchers at the Stanford University School of Medicine. [More]
Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Study shows leptomeningeal metastases more prevalent in NSCLC patients with EGFR mutations

Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. [More]
Cutting off fuel to cancer cells may be potential therapeutic strategy for Kras-driven lung cancers

Cutting off fuel to cancer cells may be potential therapeutic strategy for Kras-driven lung cancers

Research from investigators at Rutgers Cancer Institute of New Jersey and Princeton University has identified a new approach to cancer therapy in cutting off a cancer cell's 'fuel supply' by targeting a cellular survival mechanism known as autophagy. [More]
Economic crisis linked to cancer mortality increase? An interview with Dr Mahiben Maruthappu

Economic crisis linked to cancer mortality increase? An interview with Dr Mahiben Maruthappu

We found that the recent global economic crisis may have been associated with 260,000 additional cancer deaths in the OECD, between 2008 and 2010 alone. [More]
Immunotherapy innovations in oncology: an interview with Robert LaCaze

Immunotherapy innovations in oncology: an interview with Robert LaCaze

The body’s immune system is an excellent weapon against many diseases. For more than 100 years, immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer. [More]
Oncolytic virotherapy medicine shows positive treatment outcomes in late-stage cancer patients

Oncolytic virotherapy medicine shows positive treatment outcomes in late-stage cancer patients

The surprisingly positive treatment outcomes using Rigvir virotherapy for late stages cancer patients were recently published. [More]
Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Wistar scientists discover marker for PMN-MDSCs in the blood of cancer patients

Myeloid-derived suppressor cells (MDSCs) are a population of immune cells that have been implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy. [More]
Scientists identify new way to impair tumour growth in lung cancer

Scientists identify new way to impair tumour growth in lung cancer

Researchers from the Cancer Science Institute of Singapore at the National University of Singapore, in collaboration with Harvard Stem Cell Institute, have discovered a new way in which the development of lung cancer can be stopped. [More]
Research could help develop better therapies for new subtype of adenocarcinoma  patients

Research could help develop better therapies for new subtype of adenocarcinoma patients

Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. [More]
PD-1-responsive T cells may offer clues to design more effective drugs for cancer

PD-1-responsive T cells may offer clues to design more effective drugs for cancer

Cancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs. [More]
Advertisement